Day: December 10, 2021

10 December 2021Vestjysk Bank A/S has signed a loan agreement for DKK 150 million in Senior Non-Preferred Debt with a value date of 10 December 2021. The loan has a term of five years with optional prepayment after four years at the earliest, subject to prior permission from the Danish FSA. The loan carries a floating semi-annual coupon rate of CIBOR6 plus a credit spread of 200 bps. The loan agreement is a step in the ongoing optimisation of Vestjysk Bank’s capital structure. Please direct any questions regarding this announcement to Jan Ulsø Madsen, CEO, on tel. (+45) 96 63 21 04.Vestjysk Bank A/S Kim Duus                                          Jan Ulsø MadsenChairman                                           CEO Vestjysk Bank A/S Industrivej Syd 13C DK-7400 Herning Tel.: +45 96 63 20 00 CVR no. 34 63 13 28 www.vestjyskba...

Fingerprint Cards AB (publ) (the “Company”) has mandated Carnegie Investment Bank as Sole Bookrunner to arrange a series of investor meetings with credit investors to explore the conditions for the Company to issue senior secured bonds in the expected nominal amount of SEK 300,000,000. The net proceeds from the bond issue will be applied towards general corporate purposes, including investments in working capital and R&D to further accelerate growth. Subject to market conditions, the bond issue is expected to occur in the near future. For further information, please contact:Christian Fredrikson, President & CEOPer Sundqvist, CFO Investor Relations: +46(0)10-172 00 10, investrel@fingerprints.com Press: +46(0)10-172 00 20, press@fingerprints.com About Fingerprints Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics...

In order to strengthen its investor relations, this domain will effective immediately be organized under Group Function Treasury headed by Terranet’s new CFO Thomas Falkenberg. With this change the company also streamline its business operations to unleash and leverage the joint capabilities of its CMO Michaela Berglund, its CTO Nihat Kuecuek and its CEO Pär-Olof Johannesson to scale product launches, marketing and sales to secure customer engagements and strategic deals. About TerranetTerranet AB (Nasdaq: TERRNT-B). With a vision to save lives Terranet designs and develops a new class for vision-based sensor systems, used for road safety. It markets and delivers a software stack with features available across vehicle platforms and car models. The technology was handpicked and showcased twice at Startup Autobahn in 2021. The company is...

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer Tiragolumab is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration CITYSCAPE forms the basis of a broad tiragolumab development programme across multiple settings and tumour typesBasel, 10 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new follow-up efficacy, safety and patient-reported outcomes (PROs) data from the...

BBS-Bioactive Bone Substitutes, Company announcement, 10th December 2021 at 9:40 a.m. BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2022 During the year 2022, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows: Financial Statements Release for the year 2021 Thursday, 24 February 2022Half-year financial report January-June 2022 Thursday, 25 August 2022The Annual Report for the year 2021 will be published during the week 13/2022 The Annual General Meeting is planned to be held on Thursday, 28 April 2022. Company’s Board of Directors Plc will convene the meeting at a later date. BBS-Bioactive Bone Substitutes Oyj Ilkka Kangasniemi, CEO More information:Ilkka Kangasniemi, CEOtel. +358 40 7080 307e-mail: ilkka.kangasniemi@bbs-artebone.fi Certified Advisor: Nordic...

INVL Baltic Real Estate plans to publish information to investors in 2022 in accordance with the following calendar: 18 March 2022 – audited financial reports and annual report; 29 April 2022 – Net Asset Value and factsheet for 3 months of 2022; 19 August 2022 – Net Asset Value and semi–annual report of 2022; 31 October 2022 – Net Asset Value and factsheet for 9 months of 2022. The person authorized to provide additional information: Real Estate Fund Manager of Management Company Vytautas Bakšinskas E-mail vytautas.baksinskas@invl.com

INVL Baltic Farmland plans to publish information to investors in 2022 in accordance with the following calendar: 28 February 2022 – audited financial reports and annual report; 10 May 2022 – preliminary operating results and factsheet for 3 months of 2022; 26 July 2022 – semi-annual report of 2022; 8 November 2022 – preliminary operating results and factsheet for 9 months of 2022. The person authorized to provide additional information: Director Egle Surpliene E-mail: egle.surpliene@invaldainvl.com

Lund, December 10, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the company’s candidate drug laquinimod. Laquinimod is being developed as a new treatment for non-infectious non-anterior uveitis and has the potential to be used in the first line treatment as an add-on to steroids as well as in the second line treatment for patients that have failed steroid treatment. Preclinical data suggest that laquinimod may influence inflammatory eye diseases when given both as a tablet and directly onto the eye. Active Biotech has developed an eye-drop formulation of laquinimod with the aim to use it for the treatment of inflammatory eye diseases, initially in patients with non-infectious non-anterior uveitis. These...